MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below ...
Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 ...
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion ...
By Puyaan Singh and Christy Santhosh Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...
CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results